0.7456
Precedente Chiudi:
$0.7824
Aprire:
$0.79
Volume 24 ore:
424.06K
Relative Volume:
0.38
Capitalizzazione di mercato:
$36.27M
Reddito:
-
Utile/perdita netta:
$-37.65M
Rapporto P/E:
-0.4465
EPS:
-1.67
Flusso di cassa netto:
$-24.14M
1 W Prestazione:
-3.93%
1M Prestazione:
-28.31%
6M Prestazione:
-50.29%
1 anno Prestazione:
-75.31%
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Nome
Reviva Pharmaceuticals Holdings Inc
Settore
Industria
Telefono
(408) 501-8881
Indirizzo
10080 N WOLFE ROAD, CUPERTINO
Confronta RVPH con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.7456 | 36.27M | 0 | -37.65M | -24.14M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-09-20 | Iniziato | ROTH MKM | Buy |
2023-06-08 | Iniziato | The Benchmark Company | Speculative Buy |
2022-01-24 | Iniziato | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Borsa (RVPH) Ultime notizie
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Reviva Pharmaceuticals (RVPH) to Release Earnings on Monday - Defense World
RVPH: M&A Deals Highlight Brilaroxazine Value - MSN
What is Roth Capital’s Forecast for RVPH Q1 Earnings? - Defense World
Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com
Reviva Pharmaceuticals Holdings Inc. (RVPH) reports earnings - qz.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $8.00 at D. Boral Capital - Defense World
Reviva Pharmaceuticals Reports 2024 Financial Results - TipRanks
RVPH stock touches 52-week low at $0.6 amid market challenges - Investing.com Australia
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Reviva Pharmaceuticals Delays Annual Report Filing - TipRanks
Reviva Pharmaceuticals Holdings Files For Non-Timely 10-KSEC Filing - MarketScreener
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Breakthrough: Reviva's Schizophrenia Treatment Delivers Powerful 1-Year Results, Losses Narrow - Stock Titan
Reviva to Present Brilaroxazine Topline Data for Long-Term - GlobeNewswire
Major Clinical Data: 52-Week Results for New Schizophrenia Drug Coming at SIRS 2025 - Stock Titan
Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price Down 3.5% – What’s Next? - Defense World
Schizophrenia Drugs Market: Top Competitors, Market Share, - openPR.com
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Rating of “Buy” from Brokerages - Defense World
Reviva Pharmaceuticals adjusts executive pay, grants stock options By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals adjusts executive pay, grants stock options - Investing.com India
Reviva Pharmaceuticals Approves Executive Compensation Changes - TipRanks
Unusually active option classes on open February 12th - TipRanks
Get in on Reviva Pharmaceuticals Holdings Inc’s (RVPH) buy-in window today! - SETE News
Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.40 - MarketBeat
Adversity is less terrifying than hope: Reviva Pharmaceuticals Holdings Inc (RVPH) - SETE News
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Analysts - Defense World
How should investors view Reviva Pharmaceuticals Holdings Inc (RVPH)? - US Post News
Reviva Pharmaceuticals Holdings Inc (RVPH) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Reviva Pharmaceuticals to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - Nasdaq
Reviva CEO to Showcase CNS Pipeline at Major Healthcare Conference - StockTitan
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Sees Significant Decline in Short Interest - MarketBeat
Reviva to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewswire
Reviva to Participate in the 2025 BIO CEO & Investor Conference -January 30, 2025 at 08:01 am EST - Marketscreener.com
Reviva CEO Reveals Next-Gen Mental Health Drug Strategy at Major Biotech Summit - StockTitan
Is Reviva Pharmaceuticals Holdings Inc (RVPH) positioned for future growth? - SETE News
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
HC Wainwright Has Positive Outlook for RVPH FY2024 Earnings - Defense World
HC Wainwright Has Bullish Outlook for RVPH FY2024 Earnings - MarketBeat
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
HC Wainwright Issues Pessimistic Forecast for Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Receives “Buy” Rating from D. Boral Capital - Defense World
Reviva Pharmaceuticals' (RVPH) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Reviva Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Holdings Inc Azioni (RVPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):